<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02990533</url>
  </required_header>
  <id_info>
    <org_study_id>16-0146</org_study_id>
    <nct_id>NCT02990533</nct_id>
  </id_info>
  <brief_title>Muscle Anabolic Interventions to Accelerate Recovery From Hospitalization in Geriatric Patients</brief_title>
  <acronym>GRAMS</acronym>
  <official_title>Translating Muscle Anabolic Strategies Into Interventions to Accelerate Recovery From Hospitalization in Geriatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this pilot study is to collect preliminary data on the feasibility and effect&#xD;
      size of interventions to modify the physiological recovery trajectory from hospitalization in&#xD;
      community dwelling older adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this pilot study is to test the feasibility and effect size of interventions&#xD;
      to modify the physiological recovery trajectory from hospitalization in community dwelling&#xD;
      older adults.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Actual">November 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical Performance</measure>
    <time_frame>Change from Baseline to 30-day Followup</time_frame>
    <description>Short Physical Performance Battery (SPPB) scale, 0-12 points. 0=disabled; 12=high performance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Handgrip Strength</measure>
    <time_frame>Change from Baseline to 30-day Followup</time_frame>
    <description>strength by handheld dynamometer, kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Activity Level</measure>
    <time_frame>Change from Baseline to 30-day Followup</time_frame>
    <description>Number of daily steps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 day re-admission</measure>
    <time_frame>30 days post-discharge</time_frame>
    <description>Readmission within 30 days of hospital discharge</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Supplement Placebo Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo Supplement Testosterone Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protein Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protein Supplement Placebo Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protein Supplement + Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protein Supplement Testosterone Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <arm_group_label>Protein Supplement + Testosterone</arm_group_label>
    <arm_group_label>Testosterone</arm_group_label>
    <other_name>testosterone enanthate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protein Supplement</intervention_name>
    <arm_group_label>Protein Supplement</arm_group_label>
    <arm_group_label>Protein Supplement + Testosterone</arm_group_label>
    <other_name>whey protein</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Injection</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Protein Supplement</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo supplement</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Testosterone</arm_group_label>
    <other_name>maltodextrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admitted to the UTMB hospital&#xD;
&#xD;
          -  Aged 65 years or older&#xD;
&#xD;
          -  Self-reported ability (with or without the aid of an assistive device) to walk across&#xD;
             a small room two weeks prior to hospitalization&#xD;
&#xD;
          -  Alert and oriented x3 by a physician on H&amp;P.&#xD;
&#xD;
          -  Discharged &quot;to home&quot; at hospital discharge. Participation in the study will be&#xD;
             terminated in those subjects not discharged to home after hospital stay.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A Nursing home resident or hospice care patient&#xD;
&#xD;
          -  Uncontrolled blood pressure (systolic &gt;170, or diastolic &gt; 100)&#xD;
&#xD;
          -  New onset motor disability that prevents walking at the time of baseline testing&#xD;
             (stroke with motor disability, lower limb orthopedic dx)&#xD;
&#xD;
          -  End stage renal disease&#xD;
&#xD;
          -  AST/ALT 2.5 times above the normal limit&#xD;
&#xD;
          -  Recent (within 3 months) or current treatment with anabolic steroids.&#xD;
&#xD;
          -  History of breast or prostate cancer&#xD;
&#xD;
          -  Palpable prostate nodule or induration or prostate specific antigen (PSA) ≥ 4 ng/ml&#xD;
             (PSA ≥ 3 ng/ml in men at high risk of prostate cancer)&#xD;
&#xD;
          -  Hematocrit ≥ 50%&#xD;
&#xD;
          -  Any other condition or event considered exclusionary by the PI and faculty physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Volpi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UTMB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jennie Sealy Hospital</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2016</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

